A new American kindred with amyloidosis was found by single-strand conformation polymorphism analysis to have a mutation in the fibrinogen Aa chain gene. Affected members in this kindred have autosomal dominant amyloid nephropathy. DNA sequencing showed a single nucleotide deletion at the third base of codon 524 of the fibrinogen Aa chain gene (4904delG) that resulted in a frame shift and premature termination of the protein at codon 548. Antiserum was produced to a portion of the abnormal peptide predicted by the DNA sequence and amyloid deposits were immunohistologically proven to contain this abnormal peptide. Two YSTEMIC AMYLOIDOSIS has been described in many S kindreds as an autosomal dominant trait associated with mutations in a number of plasma proteins including transthyretin, apolipoprotein AI, cystatin C, fibrinogen Aa chain, and lysozyme.' The most frequent form of hereditary systemic amyloidosis is peripheral neuropathy and cardiomyopathy caused by variants of transthyretin, in which more than 40 mutations have been described at the DNA level.* However, the kidney is affected in relatively few individuals with transthyretin amyloidosis. This finding is poorly understood because primary (AL) amyloidosis and secondary (AA) amyloidosis, which are also caused by circulating plasma proteins, frequently show nephropathy as one of the main manifestation^.^.^ Hereditary renal amyloidosis (HRA), although a heterogeneous disease, can be identified as a unique entity because all affected individuals have nephropathy. This is unlike transthyretin amyloidosis, in which some individuals have cardiomyopathy, some have nephropathy, and some have only neuropathy or vitreous opacities. Since a German kindred with HRA was originally described by Ostertag in 1932: several kindreds have been reported. Although apolipoprotein AI variants were shown to be associated with the disease in two kind red^,^.' precursor proteins responsible for the amyloid deposition in most cases had been left unknown. Recently, we identified a carboxyl terminal fragment of fibrinogen Am chain with an amino acid substitution (Leu 554) in kidney amyloid deposits in a Peruvian patient with HRA' and subsequently reported another mutation that codes for an amino acid substitution in the same region of the protein (Val 526) in two Irish-American kindreds with HRA.9
though a heterogeneous disease, can be identified as a unique entity because all affected individuals have nephropathy. This is unlike transthyretin amyloidosis, in which some individuals have cardiomyopathy, some have nephropathy, and some have only neuropathy or vitreous opacities. Since a German kindred with HRA was originally described by Ostertag in 1932: several kindreds have been reported. Although apolipoprotein AI variants were shown to be associated with the disease in two kind red^,^.' precursor proteins responsible for the amyloid deposition in most cases had been left unknown. Recently, we identified a carboxyl terminal fragment of fibrinogen Am chain with an amino acid substitution (Leu 554) in kidney amyloid deposits in a Peruvian patient with HRA' and subsequently reported another mutation that codes for an amino acid substitution in the same region of the protein (Val 526) in two Irish-American kindreds with HRA. 9 We report here a new American kindred with HRA and low plasma fibrinogen concentration and describe biochemical and histologic studies on this kindred.
CASE REPORTS
A 41-year-old woman (III-2, Fig 1) noticed general fatigue and was found to have grade 3 proteinuria. In the following year, she developed lower extremity edema. She was 168 cm tall and weighed 80 kg. Her physical condition was entirely within normal limits, especially having no enlargement of the tongue, normal reflexes, and no evidence of peripheral neuropathy. She had no orthostatic hypotension. Her 24-hour urine protein excretion level was 5.068 g. She had a hemoglobin of 12.8 g, a white blood cell count of 6,100, and a normal platelet count and sedimentation rate. Her creatinine was 0.9 mg/dL. She had hyperlipidemia consistent with nephrotic of the propositus' 4 children were positive for the mutant fibrinogen Aa chain gene by restriction fragment length polymorphism analysis based on polymerase chain reaction. These two mutant gene carriers now in the second decade of life show no clinical symptoms of amyloidosis as yet but have lower plasma fibrinogen concentrations when compared with their normal siblings. This is the first description of a kindred with renal amyloidosis and low plasma fibrinogen and also the first report of amyloidosis caused by a frame shift mutation.
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syndrome. No monoclonal Ig was found in serum or urine after repeated immunoelectrophoreses and immunofixation. A hemostatic survey showed a prothrombin time of 19 seconds (normal range, 17 to 19 seconds), a thrombin time of 25 seconds (control, 20 seconds), a reptilase time of 21 seconds (control, 18 seconds), and a calcium thrombin time of 14 seconds (control, 12 seconds). The level of factor X was 117% (45% to 155%). A renal biopsy showed amyloid deposits in glomeruli. An echocardiogram showed no features of amyloid heart disease.
Over the next 4 years, her urinary protein loss continued to increase and was 14.55 g/24 h by 46 years of age. Her serum creatinine level had also increased to 4.3 mg/dL. An endomyocardial biopsy was performed because of progressive dyspnea on exertion. There was no evidence of amyloid by Congo red staining. Two rectal biopsies and a bone marrow biopsy did not show amyloid deposits. She developed cardiac failure in addition to progressive renal insufficiency at the 46 years of age. An autopsy showed extensive amyloid deposits in both kidneys and hypertrophic cardiomyopathy without amyloid deposition.
Her mother ) also died at 38 years of age of renal amyloidosis.
One of her mother's three brothers (II-1) died of renal failure at 41 years of age, but no further information was available. The propositus' 4 children (IV-1, -2, -3, and -4), who are in the second or third decade of life, have no symptoms of renal dysfunction or clotting disorder.
MATERIALS AND METHODS
DNA isolation. Total genomic DNA was isolated from peripheral blood cells of the propositus (111-2), her father , sister (III- 3). and 4 children (IV-I, -2, -3. and -4) using the conventional method. I" Single-srrand conformation polymorphism (SSCP) analysis. SSCP analysis was used to screen DNAs of patients with amyloidosis for a mutation in the fibrinogen A a chain gene." One hundred twenty normal control subjects were also tested by this method. A region of exon 5 of the gene (nucleotides 4832 through 5051) that codes a segment of the carboxyl terminus of the a chain (residues 500 through 573) was enzymatically amplified using polymerase chain reaction (PCR) directly incorporating radioactive nucleotide. PCR was performed using primers (Fib3 primer, 5'-CTTCGACAC-TGCCTCAACTG-3'; and Fib2 primer, 5'-TCCTCTGTTGTA-ACTCGTGCT-3'). GeneAmp PCR reagents (Perkin-Elmer Cetus, Nonvalk, CT), and "P-labeled dCTP (Dupont NEN, Boston, MA). PCR conditions were 30 cycles of denaturing at 94°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 1 minute. PCR products were diluted with 100 vol of buffer containing SO% formamide, O.OS% sodium dodecyl sulfate (SDS), 0.02% xylene cyano1 FF, 0.02% bromophenol blue, and 10 mmol/L EDTA. The PCR products were then heated at 95°C for 5 minutes and loaded onto a nondenaturing polyacrylamide gel (5% T, 2% C, 40 X 20 X 0.04 cm). The gel was electrophoresed at 4°C for 18 hours at 3 W, dried, and exposed to Kodak X-Omat film (Eastman Kodak, Rochester, NY).
DNA fragments containing a part of the fibrinogen A a chain gene were amplified from the patient's DNA by PCR as described above. They were then separated by the electrophoresis through 4% Nusieve GTG agarose gel (FMC BioProducts, Rockland, ME) and the band was excised and melted in 300 p L of TE buffer (10 mmol/L Tris, I mmol/L EDTA, pH 8.0). Asymmetric PCR was performed using 1 p L of the gel-purified template and the same sets of primers (primer ratio, 130). The sample was extracted with chloroform and subjected to spin dialysis with a Centricon-30 concentrator (Amicon, Beverly, MA). Seven microliters of the retentate was directly used for dideoxynucleotide DNA sequencing by Sequenase Version 2.0 (US Biochemicals, Cleveland, OH).
Because the nucleotide deletion does not create or abolish a restriction endonuclease site to distinguish the mutant allele from normal allele, DNAs from the family members were examined by PCR-induced Direct DNA sequence analvsis.
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mutation restriction analysis (PCR-IMRA)." A new primer designed to give a recognition site for Hincll in the mutant gene (Fib5 primer S'-ATGTTAGGAGAGTTTGTCAGTTA-3') was synthesized. This primer has a T instead of a normal G at the second position from the 3' end and therefore creates a Hiricll recognition site only when the fibrinogen A a gene is missing a G at position 4904.'' PCR was performed with this new primer and Fib2 primer under the same conditions as described above. Ten units of restriction endonuclease HinclI (New England Biolabs Inc. Beverly. MA) was directly added to 10 p L of PCR products and incubated at 37°C overnight. These samples were electrophoresed through 4 9 Nusieve GTG agarose gel, stained with ethidium bromide. and photographed over UV light.
A 13 amino acid length peptide (CAQNLASSQIQRN) corresponding to residues 528 through 540 of the abnormal fibrinogen A a chain sequence was synthesized linked at the C-terminus to an 8-branch MAP resin on a 432A Peptide Synthesizer (Applied Biosystems Inc, Foster City, CA) according to the manufacturer's protocol. A rabbit was immunized with the cleaved synthetic MAP-peptide and antiserum was collected. Ten milligrams of this peptide was coupled with 2 mL of Affi-Gel 10 gel (Bio-Rad Laboratories, Hercules. CA) in 0.1 mol/L MOPS [3-(N-morpholino) propane sulfonic acid] buffer (pH 7.5) according to the manufacturer's instruction. Ten milliliters of the rabbit anti-MAP peptide antiserum dialyzed against 0.1 molL sodium phosphate buffer (pH 7.2) was loaded onto the column. The column was washed with I molL NaSCN and 0.5% Triton X-100, and the bound antibody was eluted with glycine-HCI (pH 2.5).
Formalin-fixed and paraffin-embedded kidney specimens obtained from the propositus at the autopsy were used for Congo red stain or immunohistochemical staining. Kidney specimens from patients with Ig light chain-related amyloidosis and fibrinogen A a chain Val 526 amyloidosis were used as control. Congo red staining was performed by the conventional method." For immunohistologic examination, specimens were deparaffinized and incubated with S pg/mL affinity-purified rabbit antisynthetic peptide Ig or with I : 2 , 0 diluted commercial polyclonal rabbit antihuman fibrinogen (Calbiochem. San Diego, CA). They were then stained with an avidin-peroxidase immunostaining kit (Vectastain: Vector Laboratories Inc. Burlingame, CA) according to the supplier's protocol.
Plasma fibrinogen values of the propositus' father, sister, spouse, and 4 children were examined functionally by fibrin formation and immunologically by radial immunodiffusion.'""' Thrombin and reptilase clotting times were performed as described previously."
Three microliters of plasmas from the 4 children were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto nitrocellulose membrane. The membrane was incubated with polyclonal rabbit antihuman fibrinogen diluted 1:500 for 2 hours and then in alkaline phosphatase-labeled goat antirabbit Igs (BioSource International, Camarillo, CA) diluted 1: 1 , 0 for 2 hours. Color was developed using AP Color Development Reagent (Bio-Rad).
Purificarion of plasma fibrinogen and CNBr cleavage. Fibrinogen was isolated from plasma as previously described.' Briefly, 30 mL of plasma anticoagulated with trisodium citrate was obtained from one of the propositus' children identified as a mutant fibrinogen A a gene camer by DNA analysis. Plasma was passed through a lysine sepharose 4B column and a gelatin sepharose 4B column (Pharmacia, Uppsala, Sweden) and fibrinogen was precipitated with 25% ammonium sulfate. Purified fibrinogen was treated with cyanogen bromide and fractionated on a Sephadex (3-50 superfine column. Peaks eluting after the large void volume peak were pooled and fractionated on an Ultrasphere-ODS column (Beckman Instruments, Inc, Fullerton, CA). Isolated peptides were sequenced on an Applied Productiori and purification of specific aritihody.
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RESULTS
SSCP analysis showed an abnormally migrating band in the propositus' sample (Fig 2) . This abnormal band was not observed in any normal control subject tested.
Direct DNA sequencing of PCR products showed both a normal gene sequence and a mutant gene sequence with a nucleotide deletion at position 4904 of the fibrinogen Aa gene'3 that corresponded to the third base of codon 524"' (Fig 3) . This mutant gene codes for a completely abnormal peptide after codon 524 of fibrinogen Aa chain and creates a new termination codon at 548 (Fig 4) . PCR-RFLP analysis showed that 2 of propositus' children had the HincII recognition site associated with the deletion and therefore had a digestion band of 148 bp in addition to a normal band of 171 bp, whereas 2 other children showed only a normal band (Fig 5) . The propositus' healthy father and sister showed a normal digestion pattern (data not shown).
Microscopic examination of Congo red-stained sections showed Congo-phillic amorphous deposits in glomeruli ( Fig  6A) . Only a few foci of residual relatively normal glomeruli remained.
Immunohistochemical staining with the antisynthetic MAP peptide antibody showed a moderately strong immunoreactive product in the amyloid deposits in glomeruli ( Fig  6B) . This staining was absent when the antibody was preabsorbed with the synthetic peptide. Neither Ig nor fibrinogen Aa chain Val 526 amyloid deposits were stained with this antibody. Polyclonal antihuman fibrinogen failed to stain the amyloid deposits in kidney from the propositus in this study and from a patient with fibrinogen Aa chain Val 526.
The plasma fibrinogen concentrations in individuals with the fibrinogen mutation measured by both functional and immunochemical assays were below or at the low end of the normal range and lower than those in their normal siblings ( Table 1) . Thrombin and reptilase clotting times were also prolonged. Western blotting analysis of plasma after SDS-PAGE showed identical patterns in all 4 of the propositus' children and no additional band was observed in the 2 children who were predicted to have abnormal fibrinogen.
In an attempt to identify the abnormal Aa chain in plasma fibrinogen, purified fibrinogen was treated with CNBr and fractionated on a Sephadex G50 superfine column. The residue 5 18-584 CNBr from normal fibrinogen Aa chain elutes from the column in a peak after the large void volume peak that contains the large disulfide bridged fragment of fibrinogen. The abnormal Aa chain should yield a smaller CNBr fragment (residue 518 through 547) that should elute with or later than the normal Aa chain fragment. All peaks from the Sephadex column after the void volume and up to the column volume were pooled and further fractionated by high performance liquid chromatography (HPLC) before sequence analysis. Although the normal residue 518-584 Aa chain fragment and other CNBr fragments were identified, no abnormal residue 5 18-547 Aa chain peptide was found.
DISCUSSION
Fibrinogen is a 340-kD plasma glycoprotein that plays a major role in the process of blood coagulation through its conversion into fibrin.'' It consists of two identical ensem- verely prolonged. The functional fibrinogen value was lower than the immunologic value and the immunologic value itself was much lower than that of normal plasma. An Arg 554 to Cys mutation was found in a kindred showing recurrent thrombosis." The thrombin clotting time was prolonged as well as the reptilase clotting time in patients heterozygous for the mutation. A Caucasian girl suffering autoimmune hemolytic anemia, systemic lupus erythematosus, recurrent thrombophlebitis of the legs, and pulmonary embolism was found to be homozygous for a mutant fibrinogen A a chain gene with a nucleotide insertion at codon 452." Her parents and brother were heterozygotes. Her plasma was not clotted by thrombin or reptilase within 2 minutes, whereas clotting times in the heterozygotes were significantly prolonged. A marked difference between the fibrinogen content determined by a functional assay and by electroimmunoassay was reported in all affected members. Three families have been described with fibrinogen A a chain mutation associated with HRA without evidence of any clotting disorder (Leu 554, Val 526)."' Although no data on clotting were available for individuals with the Leu 554 -171 mutation, both thrombin and reptilase clotting times and plasma fibrinogen concentration by immunologic and functional methods were normal for individuals with the Val 526 mutation. Because it is unlikely that the 5' end of the gene that codes the first 19 amino acid portion is more susceptible to mutation than the rest of the gene, the high number of mutations found in this part of the gene is probably due to the fact that this region has been well searched for mutations when dysfibrinogen was suspected, whereas most mutations in the rest of the gene do not show clinical symptoms.
Hypofibrinogenemia is a term usually used when plasma fibrinogen is less than 150 mg/dL measured immunologically, electrophoretically, or by other physicochemical methods." Plasma fibrinogen levels in the mutant gene carriers in this kindred of HRA are lower than those of noncamer siblings, but do not completely meet the criteria of hypofi- Although no specimen from the propositus' mother (II-5, Fig l) , who is the other affected member in this kindred, was available for DNA testing, she is presumed to have been a mutant gene carrier because the propositus' father (II- 4) does not have the mutant gene. Factors supporting the pathogenic role for the mutation include the following: (1) association of the mutation and amyloidosis in two generations, (2) SSCP analysis of controls suggested that this DNA deletion is not a common polymorphism in the population, (3) amyloid deposits in this kindred were immunohistochemically stained with antisera raised to the abnormal fibrinogen peptide, and (4) previous studies have shown the linkage between renal amyloidosis and two other mutations in this portion of the gene."^^ Many kindreds with familial systemic amyloidosis have been reported. Most of them have transthyretin mutations associated with neuropathy and cardiomyopathy. The kindred described here is the fourth to be described with fibrinogen Aa chain amyloidosis and all show nephropathy without signs of other organ involvement. The disease in these kindreds is similar to the kindred described by Ostertag: but differs by not having hepatosplenomegaly.
Affected members in the kindred described here developed renal dysfunction in their late 30s and early 40s. This onset age is later than that of fibrinogen Aa chain Leu 554 patients who were affected in their 20s or 30s and earlier than the disease in fibrinogen Aa chain Val 526 individuals who developed the disease in the fifth to seventh decade of life.
As with other renal diseases, renal failure due to fibrinogen amyloidosis has been treated with hemodialysis. One patient with fibrinogen Aa chain Leu 554 received a kidney transplant for renal failure. The kidney functioned for 10 years but then failed due to recurrence of amyloidosis. This suggests that kidney transplantation can be a possible option for patients with hereditary amyloidosis of fibrinogen type, if the age of the patient is considered. In patients with transthyretin related amyloidosis, liver transplantation has been performed and the results are so far promising as a potentially curable treatment for the di~ease.'~ Because fibrinogen is also largely synthesized in the liver, amyloidosis patients with variant fibrinogen may also be candidates for liver transplantation.
In a previous study, we isolated a fragment of fibrinogen Aa chain (amino acid residues 500 through 580) with an amino acid substitution (Fib Aa Leu 554) from renal amyloid deposits in an individual of Peruvian descent. Although insufficient tissue was available in the present case for biochemical studies, immunohistologic studies indicated the presence of the predicted abnormal peptide in amyloid deposits. Polyclonal antihuman fibrinogen antiserum failed to stain amyloid deposits of this patient. Because the antiserum did not stain amyloid deposits of a patient with Val 526 mutation either, it seems likely that the antiserum, although it was polyclonal, did not recognize the region of Aa chain deposited in amyloid. In heterozygous patients with transthyretin-related amyloidosis, amyloid deposits have been shown to include normal as well as variant tran~thyretin.~' We do not know if the amyloid of this kindred contains normal fibrinogen as well as the abnormal peptide. If it is assumed that the amyloid peptide in this kindred starts at approximately amino acid position 500, as determined in a patient with fibrinogen Aa chain Leu 554, the abnormal peptide would share 25 amino acid residues of the normal sequence with fibrinogen Aa chain Leu 554 or Val 526 and have 23 residues of completely different sequence to the early termination. Although computer analysis of this abnormal peptide predicts P-strand structure in this 23 amino acid region, it is reasonable to assume that the normal 25 amino acid sequence (residues 500 through 524) that is shared by all three amyloidogenic fibrinogens plays an important role in amyloidogeneity. Further study based on x-ray crystallography may help to answer this question.
Another factor that must be considered in amyloidogenesis of this abnormal fibrinogen Aa chain is effects on metabolism of the protein. It has been reported that some abnormal fibrinogens exist at very low levels in plasma, probably due to rapid degradation. It is possible that the abnormal fibrinogen Aa chain in this kindred that is missing 14% of the normal carboxyl terminal sequence (residues 525 through 610) and has an abnormal peptide sequence of 23 amino acid residues may be degraded much more rapidly than normal protein. This may explain the findings that individuals with this mutation have low plasma fibrinogen levels and the abnormal fibrinogen is not detected in their plasma; at the same time, rapid degradation of the molecule may also cause the release of the amyloid peptide and lead to amyloid deposition in the kidney. For personal use only. on October 27, 2017. by guest www.bloodjournal.org From
